Current and future therapies for invasive aspergillosis. (June 2015)

• Record Type: Journal Article
• Authors: Bassetti, Matteo; Pecori, Davide; Della Siega, Paola; Corcione, Silvia; De Rosa, Francesco Giuseppe
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 32(2015:Jun.)
• Page Start: 155
• Page End: 165
• Publication Date: 2015-06
• Subjects: Aspergillus -- Voriconazole -- Posaconazole -- Amphotericin -- Echinocandins -- Galactomannan; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2014.06.002
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: Invasive fungal infections have increase worldwide and represent a threat for immunocompromised patients including HIV-infected, recipients of solid organ and stem cell transplants, and patients receiving immunosuppressive therapies. High mortality rates and difficulties in early diagnosis characterize pulmonary fungal infections. Invasive pulmonary aspergillosis has been reviewed focussing on therapeutic management. Although new compounds have become available in the past years (i.e., amphotericin B lipid formulations, last-generation azoles, and echinocandines), new diagnostic tools and careful therapeutic management are mandatory to assure an early appropriate targeted treatment that represents the key factor for a successful conservative approach in respiratory fungal infections.